Aquestive Therapeutics (NASDAQ:AQST) reported that the U.S. Food and Drug Administration has identified deficiencies in the new drug application for Anaphylm (dibutepinephrine), an oral sublingual film formulation for the emergency treatment of Type I allergic reactions, including anaphylaxis.
Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.
Amarin Corporation (NASDAQ:AMRN) commented on recent therapeutic advances for patients with elevated triglycerides, asserting that its flagship VASCEPA/VAZKEPA (icosapent ethyl) franchise remains strongly positioned to benefit from broader category commercialization efforts.
California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.
Lindsay Corporation (NYSE:LLN), a global heavyweight in automated irrigation systems and roadway infrastructure, announced Friday that its Board of Directors has authorized a regular quarterly cash dividend of $0.37 per share.
Liquidia Corporation (NASDAQ:LQDA) reported preliminary, unaudited commercial performance metrics for its lead product YUTREPIA (treprostinil) inhalation powder for the fourth quarter and full year ended December 31, 2025.
Meta Platforms (NASDAQ:META) said Friday it has signed 20-year power purchase agreements to buy electricity from three Vistra Corp. nuclear plants in the U.S. Midwest and entered development partnerships with two companies pursuing small modular reactor technology, as Big Tech races to lock in reliable, long-term energy supplies for expanding artificial intelligence and data center operations.
Haemonetics Corp. (NYSE:HAE) announced Friday it has acquired Vivasure Medical Limited, a Galway-based pioneer in vessel closure technology, in a move that significantly broadens its reach into the $2.5 billion global vascular closure market.
Kezar Life Sciences (NASDAQ:KZR) announced Friday that the FDA has granted a formal Type C meeting for the first quarter of 2026, a move that could revive the clinical path for its lead asset, zetomipzomib, following months of regulatory uncertainty.
ChipMOS TECHNOLOGIES (NASDAQ:IMOS) reported a sharp rise in fourth-quarter revenue on Friday, as the specialized semiconductor packager benefits from a "perfect storm" of high-density memory demand and a strategic shift toward AI-related infrastructure.
Sanuwave Health (NASDAQ:SNWV) reported preliminary fourth-quarter revenue that reached an all-time high, as the medical device maker effectively navigated a volatile reimbursement landscape that has left many of its competitors in the wound-care sector reeling.
Taiwan Semiconductor Manufacturing Company (NYSE:TSM), the world's largest contract chipmaker, reported fourth-quarter revenue that rose 20.45% from the year-ago period on surging interest in artificial intelligence applications.
%2520inhalation%2520powder-640x640.png&w=3840&q=75)
